ClariVest Asset Management’s Beam Therapeutics BEAM Stock Holding History

ClariVest Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$300K	Hold	12,816	–	–	0.03%	369
2024 Q2	$300K	Sell	12,816 -28	-0.2%	-$688	0.03%	369
2024 Q1	$424K	Buy	12,844 +13	+0.1%	+$405	0.04%	366
2023 Q4	$349K	Sell	12,831 -2,319	-15%	-$57.6K	0.02%	373
2023 Q3	$364K	Sell	15,150 -22,690	-60%	-$608K	0.02%	362
2023 Q2	$1.21M	Sell	37,840 -5,700	-13%	-$185K	0.06%	206
2023 Q1	$1.33M	Buy	43,540 +21	+0%	+$829	0.06%	241
2022 Q4	$1.7M	Sell	43,519 -137	-0.3%	-$6.14K	0.08%	184
2022 Q3	$2.08M	Sell	43,656 -2,593	-6%	-$148K	0.1%	159
2022 Q2	$1.79M	Buy	+46,249	New	+$1.84M	0.08%	203

Other funds holding BEAM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

ClariVest Asset Management's BEAM Position: Q3 2024 in Review

ClariVest Asset Management held its Beam Therapeutics (BEAM) position steady in Q3 2024 at 12,816 shares worth $300K. The position accounts for 0.03% of the portfolio, ranked #369.

ClariVest Asset Management first reported a position in BEAM in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.08M in Q3 2022. 221 funds tracked by Wall St. Rank hold BEAM as of Q3 2024.

ClariVest Asset Management held 12,816 shares of Beam Therapeutics worth $300K as of Q3 2024.
ClariVest Asset Management left its Beam Therapeutics share count unchanged in Q3 2024.
Beam Therapeutics made up 0.03% of ClariVest Asset Management's portfolio in Q3 2024, its #369 holding.
ClariVest Asset Management first reported a position in Beam Therapeutics in Q2 2022 and has held it in 10 quarters since.
ClariVest Asset Management's Beam Therapeutics position peaked at $2.08M in Q3 2022.
221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.